Thus, patients whose tumours have EGFR CNG and/or EGFR protein overexpression represent a subgroup that potentially benefits from EGFR inhibitor monotherapy [5, 10], (HR for death, 0.21; 95% CI, 0.07 to 0.64; P = 0.006) [5]. Here, EGFR is linked to neoplasm.